Preclinical studies have shown that activation of the EGFR pathway leads to the upregulation of immune checkpoint molecules such as PD-L1 on tumor cells, which consequently allows them to evade immune-mediated cytotoxicity [8,9]. Here, EGFR is linked to neoplasm.